Angiogenesis is crucial to restore microvascular perfusion in the jeopardized myocardium in the weeks following reperfused ST-segment elevation myocardial infarction (STEMI). (VEGF)-A 165 b, an anti-angiogenic factor, has been identified as a regulator of vascularization; however, it has not been previously implicated in acute myocardial infarction. We sought to investigate the dynamics of circulating VEGF-A 165 b and its association with cardiac magnetic resonance-derived infarct size and left ventricular ejection fraction (LVEF). 50 STEMI patients and 23 controls were included. Compared with control individuals, serum VEGF-A 165 b was elevated in STEMI patients prior to primary percutaneous coronary intervention (PCI). Following PCI, serum VEGF-A 165 b increased further, reaching a maximum level at 24 h and decreased one month after reperfusion. VEGF-A 165 b levels at 24 h were associated with a large infarct size and inversely related to LVEF. VEGF-A 165 b expression was increased in myocardial infarct areas from patients with previous history of AMI. An ex vivo assay using serum from STEMI patients showed that neutralization of VEGF-A 165 b increased tubulogenesis. Overall, the study suggests that VEGF-A 165 b might play a deleterious role after AMI as an inhibitor of angiogenesis in the myocardium. Accordingly, neutralization of VEGF-A 165 b could represent a novel pro-angiogenic therapy for reperfusion of myocardium in STEMI.
fails to activate receptor phosphorylation, consequently impairing angiogenesis 11, 12 . In humans, downregulation of VEGF-A 165 b has been documented in a large number of angiogenic pathological states such as proliferative diabetic retinopathy 13 and cancer 12, [14] [15] [16] . Conversely, increased levels of VEGF-A 165 b have been associated with impaired vascularization in patients with peripheral artery disease [17] [18] [19] and systemic sclerosis 20 . However, there have been no reports examining the VEGF-A 165 b isoform in AMI.
In the present study, we hypothesized that circulating levels of VEGF-A 165 b are altered after AMI and might reflect the extent of LV damage. Additionally, we hypothesized that functional blockade of VEGF-A 165 b in STEMI could boost angiogenesis.
Therefore, the objectives of this study were the following: 1) to evaluate in a prospective series of STEMI patients managed according to current recommendations, the temporal changes in circulating VEGF-A 165 b, and 2) its association with the presence of extensive LV damage as derived from the two most validated indices (LV ejection fraction [LVEF] and infarct size) using cardiac magnetic resonance (CMR); 3) to determine whether VEGF-A 165 b protein expression can be detected in human heart tissue of patients with previous history of AMI; and 4) to investigate the effects of VEGF-A 165 b blockade on angiogenesis using serum from STEMI patients in ex vivo assays.
Results
Blood samples were obtained from 50 STEMI patients and 23 control subjects. Data regarding patients' recruitment and blood sampling are shown in Fig. 1A and B , respectively. The characteristics of STEMI patients are shown in Table 1 .
VEGF-A 165 b levels are increased in the circulation of STEMI patients. To investigate the temporal changes in serum VEGF-A 165 b levels, we performed repeated measurements at defined intervals in the first twenty STEMI patients and twenty controls included in our final study group. The serum concentration of VEGF-A 165 b upon patients' arrival (before percutaneous coronary intervention [PCI], 0 h) and at 24 h, 96 h and 1 month after reperfusion therapy are shown in Fig. 2 . Circulating VEGF-A 165 b levels, even before reperfusion, were significantly higher in STEMI patients (median 64.46 pg/mL, range 0 to 401.3 pg/mL, p < 0.01) than in controls (median 6.36 pg/mL, range 0 to 74.4 pg/mL). VEGF-A 165 b levels peaked 24 h after reperfusion (median 103.3, range 4.5 to Table 1 . Baseline characteristics, therapies at discharge and CMR characteristics of STEMI patients. Values represent mean ± SD or the percentage of patients. PCI, percutaneous coronary intervention; LVEF, left ventricular ejection fraction; CMR, cardiac magnetic resonance; TIMI, thrombolysis in myocardial infarction; ACE, angiotensin converting enzyme; AR, angiotensin receptor; BMI, body mass index; GFR, glomerular filtration rate; PAD, peripheral artery disease.
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VEGF-A 165 b levels are elevated in STEMI patients with large infarct size and reduced LVEF.
Once the time course of VEGF-A 165 b was defined in the first 20 STEMI patients, and taking into account that VEGF-A 165 b levels peaked 24 h after reperfusion, we sought to evaluate the relationship between VEGF-A 165 b at this time point and the presence of structural damage in pre-discharge CMR. To do this, we extended the study group to 23 controls and recruited 30 additional STEMI patients in whom blood samples were obtained at 24 h. Once again, in the whole study group, serum VEGF-A 165 b levels at 24 h were significantly higher in STEMI patients (n = 50) than in controls (n = 23) (p < 0.01) ( Fig. 3A) . Additionally, we measured total VEGF-A in both groups. VEGF-A levels were significantly higher in STEMI patients (median 110.4 pg/mL, range 13.9 to 485.3 pg/ mL, p < 0.01) than in controls (median 45.83 pg/mL, range 0 to 153.7 pg/mL) ( Fig. 3B ). When we evaluated the ratio of VEGF-A 165 b/VEGF-A, we observed a significant 2-fold increase in VEGF-A 165 b in STEMI versus controls ( Fig. 3C , p < 0.05), indicating that total VEGF-A includes □ 60% VEGF-A 165 b fraction in STEMI patients. Moreover, there was a significant association between VEGF-A 165 b serum levels and infarct size (r = 0.36, p = 0.01, Fig. 3D ) and an inverse correlation with LVEF (r = −0.34, p = 0.02, Fig. 3E ).
VEGF-A 165 b is upregulated in the infarct areas in patients with a previous history of AMI.
Immunohistochemical studies were performed to assess the expression of VEGF-A 165 b in human heart samples. Myocardial sections from four patients with old myocardial infarction (OMI) and five control subjects were immunostained with a mouse monoclonal antibody that specifically detects the VEGF-A 165 b splice variant 20 . The baseline characteristics and autopsy results of patients are described in Table 2 . History of AMI had been previously documented in all patients and autopsies unequivocally revealed fibrotic scar tissue characteristic of chronic infarct in all cases. Previous history of ischemic or any other cardiac diseases in controls had been ruled out both in the clinical records and in the autopsy analyses.
Consistent with our previous findings 21 , histological evaluation of heart sections by picrosirius staining showed myocardial fibrosis and extensive collagen deposition within the infarcted areas ( Fig. 4A ). Of interest, whereas a weak constitutive expression of VEGF-A 165 b was observed mainly in endothelial cells in myocardial sections from controls, a marked upregulation of VEGF-A 165 b endothelial expression was observed in infarct samples from AMI patients (Fig. 4A ). Quantification of immunostaining revealed that VEGF-A 165 b expression was significantly higher in infarcted myocardial sections than in control sections ( Fig. 4B , p < 0.05). Furthermore, double labeling immunofluorescence using an endothelial antibody confirmed the expression of VEGF-A 165 b in endothelial cells (CD31+) ( Fig. 4C ). Additionally, coexpression of VEGF-A 165 b and VEGFR-2 was detected in infarcted myocardium regions ( Fig. 4C ).
Neutralization of VEGF-A 165 b activity in serum from STEMI patients increases endothelial network formation.
Previous studies have shown that VEGF-A 165 b binds to VEGFR-2 and inhibits angiogenesis elicited by proagiogenic VEGF-A 165 in several types of endothelial cells 18, 20, [22] [23] [24] [25] . However, its effect on human coronary artery endothelial cells (HCAEC) remains unknown. We thus carried out an in vitro endothelial differentiation assay 26, 27 to assess the impact of recombinant VEGF-A 165 b on HCAEC differentiation into capillary-like structures. We first confirmed that VEGFR-2 protein was expressed in HCAEC by western blotting (Fig. 5A ). We found that the ability of HCAEC to form tubular-like structures was markedly enhanced in the presence of the angiogenic human recombinant VEGF-A 165 isoform for 24 h (74.9±19.0 vs control 43.3±13.0, p < 0.01, Fig. 5B ). Of note, whereas treatment of HCAEC with VEGF-A 165 b alone did not impact angiogenesis, cotreatment of HCAEC with VEGF-A 165 b significantly reduced the angiogenic response triggered by VEGF-A 165 (p < 0.05, Fig. 5B ).
Given that proliferation and migration of endothelial cells are essential steps in angiogenesis, we also studied the effect of VEGF-A 165 b on these parameters. In the proliferation assay, we observed that treatment of HCAEC with human recombinant VEGF-A 165 significantly increased the proliferation of HCAEC (64.9±13.0% vs 37.3±6.5% in controls, p < 0.05, Fig. 5C and Supplementary Fig S1) . VEGF-A 165 b alone did not impact HCAEC proliferation, however, it significantly decreased VEGF-A 165 -induced HCAEC proliferation ( Fig. 5C and Supplementary Fig S1, p < 0.05). Additionally, we measured the effect of VEGF-A 165 b on VEGF-A 165 -mediated migration. Migration was significantly greater in VEGF-A 165 -treated endothelial cells than in vehicle-treated cells (47.9±15.9% vs 18.1±1.5% in controls, p < 0.05, Fig. 5D and Supplementary Fig S1) . Whereas VEGF-A 165 b treatment alone did not impact migration, a significant reduction in the migratory potential of VEGF-A 165 -stimulated HCAEC was observed when cells were cotreated with VEGF-A 165 plus VEGF-A 165 b ( Fig. 5D , p < 0.05).
VEGF-A 165 has been previously shown to stimulate AKT phosphorylation in endothelial cells via VEGFR-2 activation 28 . To determine whether VEGF-A 165 b modulates VEGF-A 165 -mediated signaling in human coronary endothelial cells, we treated HCAEC with vehicle, VEGF-A 165 , VEGF-A 165 b, or with both isoforms for 20 min, and then extracted proteins for western blotting. We found that AKT phosphorylation was significantly higher in HCAEC treated with VEGF-A 165 than in cells treated with vehicle ( Fig. 5E ). Whereas treatment with VEGF-A 165 b alone did not affect AKT phosphorylation in HCAEC, VEGF-A 165 b significantly reduced VEGF-A 165 -mediated phosphorylation of AKT (p < 0.05, Fig. 5E ).
Given our findings of increased circulating levels of VEGF-A 165 b in STEMI patients, we further explored the consequences of functional VEGF-A 165 b serum neutralization for angiogenesis ex vivo. In the presence of an irrelevant antibody, serum from STEMI patients showed a similar HCAEC angiogenic response to that of the control group (STEMI: 82.6±26.0 vs control: 67.8±37.7, p > 0.05) (Fig. 6A ). The addition of anti-VEGF-A 165 b neutralizing antibody, however, resulted in a significant stimulation of tubulogenesis by serum from STEMI patients as compared with control serum (STEMI: 110.7±26.3 vs control: 60.1±49.0, p < 0.01 ( Fig. 6A ). Also, an inverse association between VEGF-A 165 b levels and angiogenesis induced by serum (+IgG) from STEMI patients was also observed (r = −0.29, p = 0.03) ( Fig. 6B) . Finally, we repeated the proliferation and migration assays in HCAEC using serum from STEMI patients and controls. We again observed that the treatment with an anti-VEGF-A 165 b neutralizing antibody significantly increased the proliferation (STEMI: 67.3±18.5% vs control: 36.4±18.9%, p < 0.01 ( Fig. 6C ) and the migration (STEMI: 81.2±48.6% vs control: 52.6±35.3%, p < 0.05 ( Fig. 6D ) of HCAEC cultured in serum from STEMI patients as compared with controls.
Discussion
The endogenous VEGF-A isoform, VEGF-A 165 b, is known to inhibit endothelial proliferation and suppress tumor growth. However, little is currently known about the pathophysiology of VEGF-A 165 b in the setting of human myocardial infarction. To the best of our knowledge, ours is the first study to investigate VEGF-A 165 b expression and function in STEMI. The main findings are as follows: 1) systemic VEGF-A 165 b levels are elevated in STEMI patients; 2) elevated circulating VEGF-A 165 b levels are associated with a large infarct size and reduced LVEF in STEMI patients; 3) up-regulation of VEGF-A 165 b protein expression occurs in infarcted tissue; 4) VEGF-A 165 b blockade in serum from STEMI patients enhances angiogenesis, proliferation and migration of human coronary endothelial cells ex vivo.
Early reperfusion of the culprit coronary artery using primary PCI is the best available therapy for the management of STEMI patients. Nevertheless, despite its generalized use in western countries, severe microvascular damage can persist in a significant number of patients, resulting in larger infarctions, systolic deterioration, left ventricular remodeling, and worsening of patient outcomes 2, 29 . The development of neoangiogenesis within the myocardial infarct occurs as a response to ischemia to restore microvascular perfusion in the weeks and months following AMI, thus exerting salutary effects on infarct healing, systolic recovery and left ventricular dilation 1, 2, 30 . More knowledge on this issue is critical to better understand the pathophysiology of AMI and to develop new therapeutic opportunities beyond prompt coronary reperfusion, which can help to decrease the burden of AMI in terms of morbidity and mortality.
Angiogenesis is highly regulated and requires the orchestrated interaction of endothelial cells and surrounding cells mediated by growth factors and their receptors 3 . Among them, VEGF-A and its receptor VEGFR-2 have been shown to play major roles in many pathological scenarios that occur with angiogenesis, including AMI 8, 9 . VEGF-A expression is increased in the ischemic myocardium 6, 7 , and elevated serum VEGF-A levels have been reported in patients with STEMI 8, 9, 31 . However, VEGF-A can be differentially spliced to generate the inhibitory VEGF-A 165 b isoform, which has recently emerged as an important factor in several clinical ischemic states. Accordingly, elevated circulating VEGF-A 165 b levels have been reported in patients with peripheral artery disease [17] [18] [19] or systemic sclerosis 20 . In the present study, we demonstrate that regulation of VEGF-A splicing takes place also in the setting of myocardial ischemia since VEGF-A 165 b expression was rapidly increased at early phases after AMI to reach a maximum level 24 h after reperfusion. Given the temporal characteristics of VEGF-A 165 b expression in peripheral blood, it is tempting to speculate that VEGF-A 165 b may contribute to the impaired neovascularization in the acute phase after myocardial ischemia.
CMR has become the gold standard non-invasive cardiac imaging technique to comprehensively characterize the structural consequences of AMI 32 . In particular, cine-CMR and delayed enhancement sequences allow for state-of-the-art quantification of two potent prognostic indices in post-STEMI patients, namely LVEF and infarct size, respectively 32, 33 . Interestingly, we show in our study that VEGF-A 165 b in peripheral blood from STEMI patients is associated with a more extensive infarct. Likewise, higher VEGF-A 165 b levels are associated with reduced LVEF. Thus, up-regulation of VEGF-A 165 b expression after STEMI is associated with severe LV deterioration.
Previous studies have demonstrated that VEGF-A 165 b is down-regulated in pathological angiogenic states such as cancer and diabetic retinopathy 14, 34, 35 . Conversely, up-regulation of VEGF-A 165 b is associated with reduced neovascularization in several diseases including obesity 36 , systemic sclerosis 20 , and peripheral artery disease 18, 37 . Along this line, we show an up-regulation of VEGF-A 165 b protein expression in the infarcted myocardial tissue of patients with an OMI. In accordance with previous reports 20 , VEGF-A 165 b was mainly localized to vascular Table 2 . Clinical data and autopsy results of patients. a In patient 2, infarct size was not quantified, but was visually described in the autopsy report. endothelial cells. While we have no direct evidence that increased VEGF-A 165 b myocardial expression occurs early after MI and further research is needed, our results suggest that VEGF-A 165 b may be involved in neovessel formation late after MI. The anti-angiogenic effects of VEGF-A 165 b have been well demonstrated in a large number of experimental and human studies 14, 18, 20, 22 . In this context, VEGF-A 165 b has been shown to reduce VEGF-A 165 -induced morphogenesis in vitro in dermal microvascular endothelial cells 20 and in animal models 34, 38 . In line with these findings, we found that VEGF-A 165 b inhibited VEGF-A 165 -induced morphogenesis, proliferation and migration in human coronary endothelial cells. Additionally, we observed that VEGF-A 165 b blocked the phosphorylation (activation) of AKT induced by VEGF-A 165 in HCAEC. AKT is involved in multiple signaling pathways in the regulation of angiogenesis 39 , and is reported to be relevant as a pro-survival signal in response to cardiac hypoxia and other stimuli such as VEGF-A 39 . Therefore, our present data suggest that the anti-angiogenic effect of VEGF-A 165 b in human coronary endothelial cells could be due, at least in part, to inhibition of VEGFR-2/AKT signalling.
Our in vivo observations prompted us to evaluate the potential functional effects of VEGF-A 165 b blockade for STEMI patients. We found that neutralization of VEGF-A 165 b activity in serum from STEMI patients significantly increased the angiogenic response. Considering that pro-angiogenic therapy based on VEGF-A administration in human clinical trials has been largely unsuccessful, overall, our data suggest that functional blockade of VEGF-A 165 b might constitute a new strategy to improve neovessel formation after AMI. In agreement with this, delivery of VEGF-A 165 b reduced revascularization of the ischemic hindlimb in a murine model of peripheral artery disease, whereas treatment with a neutralizing antibody of this isoform reversed impaired revascularization 18 .
Our data suggest that regulation of splicing of VEGF-A may also be important in the context of AMI in humans, implicating a novel mechanism of VEGF-A 165 b up-regulation that may relevant for the management of patients. We speculate that the high circulating levels of VEGF-A 165 b in STEMI patients might hamper the spontaneous tendency towards recovery of microvascular perfusion and, in turn, lead to a larger infarction with more severely depressed systolic function. Our ex vivo results point in this direction and strongly suggest that VEGF-A 165 b blockade is a promising therapeutic option to accelerate neoangiogenesis in the infarcted area. Nevertheless, further mechanistic studies are required to understand the molecular pathways involved in VEGF-A 165 b-associated cardiac angiogenesis. Additionally, the limitations of the present study include the small number of measured samples and its single-center design. Replication of these findings in other cohorts is needed as a next step in evaluating the importance of VEGF-A 165 b in mediating tissue reperfusion and its relationship with patient survival.
In conclusion, we provide evidence that endogenous VEGF-A 165 b is significantly elevated in STEMI patients. To our knowledge, this is the first report on a previously unexplored anti-angiogenic factor in the context of AMI that may be involved in the pathogenesis of STEMI in humans. Therefore, pharmacological modulation of VEGF-A 165 b expression and function might be a promising therapeutic strategy to accelerate angiogenesis after AMI.
Methods
Study population. The study conformed to the principles outlined in the Declaration of Helsinki for the use of human subjects. The study protocol was approved by the Ethics Committee of the University Clinic Hospital of Valencia. Written informed consent was obtained from all subjects. Reporting of the study conformed to the STROBE statement along with references to STROBE and the broader EQUATOR guidelines 40 .
Patients were considered to be included in the study group if they were admitted to our institution with a first STEMI defined following current definitions 41 , were treated with primary PCI within 12 hours of chest pain onset, and underwent CMR imaging at pre-discharge. We prospectively enrolled 81 consecutive patients from July 2013 to July 2014 with these characteristics.
Death (n = 1), re-infarction (n = 3), clinical instability (n = 2) during admission and any contraindication to CMR (n = 6) were exclusion criteria. Therefore, the final study group comprised 50 patients. The flow chart of patients in the study is presented in Fig. 1A .
We recruited a control group matched in age and sex with the study group, made up of 23 patients in whom the presence of any cardiac disease was ruled out by means of a thorough clinical history, physical exploration and echocardiographic study carried out by a clinical cardiologist.
Baseline characteristics and serial blood samples. Baseline characteristics were prospectively regis-
tered in all cases. The PCI technique was chosen at the discretion of the interventional operator. Thrombolysis in Myocardial Infarction (TIMI) flow grade in the problem artery (before and after PCI) was analyzed 42 . Patients were managed both in-hospital and after discharge by a specific STEMI unit, and current recommendations 43 were strictly followed. Further details on patients' characteristics are shown in Table 1 .
Blood samples were centrifuged at 2300 rpm for 15 min and serum was immediately stored at −80 °C. In the first 20 patients included in the study group, sequential blood sampling was obtained upon patient arrival (before primary PCI), and at 24 h, 96 h and 1 month after primary PCI. Sequential blood samples in the first 20 STEMI patients and 20 controls were used to define the temporal course of VEGF-A 165 b levels. VEGF-A 165 b peaked 24 h post-PCI. In patients 21-50, a single blood sample collected 24 h after primary PCI was obtained. The association between VEGF-A 165 b levels at 24 h post-PCI with infarct size (% of LV mass) and LVEF (%) as derived from CMR was determined in the 50 patients included in the final study group Cardiac Magnetic Resonance. CMR (1.5 T unit, Magnetom Sonata; Siemens, Erlangen, Germany) was performed 7±2 days after STEMI, in accordance with our laboratory protocol and current recommendations 1, 32 . All studies were performed by two cardiologists specialized in CMR with 15 years of experience. An experienced observer with 3 years of experience, blinded to all patient data, analyzed the CMR data offline using customized software (QMASS MR 6.1.5, Medis, Leiden, The Netherlands). CMR data were prospectively recorded and immediately included in the registry database. LVEF (%), LV end-diastolic volume index (mL/m 2 ), LV end-systolic volume index (mL/m 2 ), and LV mass index (g/m 2 ) was calculated by manual planimetry of endocardial and epicardial borders in short-axis view cine images. Areas showing late gadolinium enhancement were visually revised and quantified by manual planimetry. Infarct size (% of LV mass) was assessed as the percentage of LV mass showing late gadolinium enhancement. Microvascular obstruction (% of LV mass) was quantified by manual planimetry and defined as the percentage of LV mass showing a lack of contrast uptake in the core of tissue showing late gadolinium enhancement. Myocardial edema was defined as areas of high T2 signal intensity. All short-axis view slices were separately analyzed and the presence of edema was visually revised, quantified by manual planimetry and expressed as percentage of LV mass. Myocardial salvage index was calculated by subtracting the mass of infarcted myocardium from myocardium showing edema and expressed as percentage of LV mass with myocardial edema.
Images were acquired by a phased-array body surface coil during breath-holds and were triggered by electrocardiography. Cine images were acquired in two-, three-, and four-chamber views, and in short-axis views using a steady-state free precession sequence (repetition time/echo time: 2.8/1.2 ms; flip angle: 58 degrees; matrix: 256 × 300; field of view: 320 × 270 mm; slice thickness: 7 mm).
Late gadolinium enhancement imaging was performed 10 to 15 minutes after administering 0.1 mmol/kg of gadolinium diethylenetriaminepentaacetic acid (Magnograf, Juste S.A.Q.F., Madrid, Spain) in the same locations as in cine images using a segmented inversion recovery steady-state free precession sequence (repetition time/ echo time: 750/1.26 ms; flip angle: 45 degrees; matrix: 256 × 184; field of view: 340 × 235 mm; slice thickness: 7 mm). Inversion time was adjusted to nullify normal myocardium.
Black blood, T2-weighted short TI inversion recovery sequences in the same short-axis view as the cine sequences, all in mid-diastole, were carried out. A half-Fourier acquisition single-shot turbo spin echo multisection sequence was used (recovery time: two R-R intervals; echo time: 33 ms; inversion time: 170 ms; slice thickness: 8 mm; interslice interval: 2 mm; flip angle: 160 degrees; matrix: 256 × 151; bandwidth: 781 Hz/pixel). Additionally, a segmented turbo-spin echo sequence was obtained with one slice per breath-hold (recovery time: two R-R intervals; echo time: 100 ms; inversion time: 170 ms; slice thickness: 8 mm; interslice interval: 2 mm; flip angle: 180 degrees; matrix: 256 × 146; bandwidth: 235 Hz/pixel).
The inter-observer variability for the calculation of traditional CMR indexes used in the present study in our laboratory has been previously reported and is less than 5% 1 . In brief, inter-observer variability was calculated by comparing the differences between the measurements performed by two experienced operators in 30 CMR studies randomly sampled from the study group.
For the purposes of the present study, to explore the association of VEGF-A 165 b with left ventricular damage following STEMI, we focused on the two CMR indexes that traditionally have been more solidly associated with patients' outcomes, namely LVEF and infarct size 7 . Endothelial differentiation assay. Growth factor-reduced Matrigel (100 µL) (BD Biosciences, Madrid, Spain) was added to tissue culture 96-well plates and polymerized for 30 minutes at 37 °C as decribed 26 . HCAEC (30 × 10 3 cells/well) were seeded into Matrigel in DMEM medium containing 2% FBS. Cells were treated with vehicle (PBS), human recombinant VEGF-A 165 (30 ng/mL; cat#293VE, R&D Systems), VEGF-A 165 b (30 ng/mL; cat#3045VE, R&D Systems) or their combination (both at 30 ng/mL).
VEGF-A
In additional experiments, HCAEC were seeded in Matrigel and incubated with diluted serum (10%) from STEMI patients (n = 50) and controls (n = 23). Additionally, samples were incubated in the presence of a mouse monoclonal anti-human VEGF-A 165 b blocking antibody (10 µg/mL, cat#MAB3045, R&D Systems) or an irrelevant isotype and concentration-matched IgG (10 µg/mL, R&D Systems) as previously described 20 . Phase contrast micrographs (Axio Observer A1, Carl Zeiss, NY) were recorded after 24 h and the number of tubes in 5 low-power (×100) random fields were counted. Scoring of tubulogenesis was performed by an investigator blinded to treatments.
BrdU proliferation assay. Proliferation assays were performed by bromodeoxyuridine (BrdU) incorporation (50 μM) as previously described 27 . HCAEC were treated with vehicle (PBS), human recombinant VEGF-A 165 (30 ng/mL), VEGF-A 165 b (30 ng/mL) or their combination (both at 30 ng/mL). In additional studies, HCAEC were seeded and incubated with diluted serum (10%) from STEMI patients and controls. Then, samples were incubated in the presence of a mouse monoclonal anti-human VEGF-A 165 b blocking antibody (10 µg/mL) or an irrelevant isotype and concentration-matched IgG (10 µg/mL). After 24 h, cells were fixed with 4% paraformaldehyde for 20 min, permeabilized with 1.0% Triton X-100 in PBS for 15 min, washed with PBS, and incubated with PBS containing 10% normal goat serum for 1 h at room temperature. BrdU-positive cells were detected by immunofluorescence with an anti-BrdU Alexa Fluor-488 antibody (Invitrogen, CA). 4′,6-diamidino-2-phenylindole (DAPI) was used for nuclear staining (total cell count). Cell proliferation was determined as the percentage of BrdU positive cells relative to total cell count.
Wound-healing migration assay. Migratory activity was assessed by a standard wound-healing migration assay. HCAEC were plated on 12-well plates to 80% confluence. At time 0 of the migration assay, a wound was made in the center of the cell monolayer using a sterile tip and cells were incubated with the different treatments as described above for 24 h. Images were taken at time 0 h and 24 h. Cell migration was calculated as wound area closure of at least 5 points at time t = 24 relative to wound area at t = 0. Analysis was performed with ImageJ software.
Western blotting. HCAEC were treated with human recombinant VEGF-A 165 (30 ng/mL; cat# 293VE, R&D Systems), VEGF-A 165 b (30 ng/mL; cat#3045VE, R&D Systems) or their combination (both at 30 ng/mL) for 20 min. After treatments, cells were lysed and protein concentration was determined using the Bradford method 44 . Samples were denatured, subjected to SDS-PAGE using a 10% running gel, and transferred to a nitrocellulose membrane. Non-specific binding sites were blocked with 3% bovine serum albumin (BSA) in TBS solution and membranes were incubated overnight with rabbit polyclonal antibodies against human VEGFR2 (1:200 dilution, cat#ab39256, Abcam, Cambridge, UK), AKT(1/200 dilution, cat#4685, Cell Signaling Technology, Danvers, MA), and phospho-AKT (Ser473) (1/200 dilution, cat#4085, Cell Signaling Technology). Membranes were subsequently washed, incubated for one additional hour with the secondary HRP-linked anti-rabbit antibody (1:2000 dilution, cat#0448, Dako, Glostrup, Denmark) and developed using an ECL procedure (GE Healthcare, Madrid, Spain). Signals were recorded using a luminescent analyzer (FujiFilm Image Reader LAS 4000, Fuji, Tokyo, Japan).
VEGF-A 165 b detection in myocardial tissue samples. Postmortem myocardial tissue was obtained from the autopsies of four patients with an OMI (samples were obtained more than 6 months after AMI occurrence). A previous history of AMI had been previously documented in all patients, and autopsies unequivocally revealed a fibrotic scar characteristic of chronic infarct in all cases. Additionally, myocardial samples of the autopsies of four patients with no evidence of myocardial infarction or other structural cardiac abnormalities were used as controls; a previous history of ischemic or any other cardiac diseases had been ruled out both in the clinical records and in the autopsy analyses. The clinical data and autopsy results of patients are described in Table 2 . Heart tissue samples were fixed in 10% formalin at 4 °C for 24 h, embedded in paraffin, sectioned (5 μm) and mounted on double gelatin-coated glass slides. Collagen deposition was detected by staining with picrosirius red. Briefly, dehydrated sections were incubated in 0.2% phosphomolydbic acid and then stained with 1% Direct Red 80 (Sigma-Aldrich, Madrid, Spain) in saturated picric acid and washed in 0.01 N hydrochloric acid as previously described 45 . For VEGF-A 165 b detection, sections were treated with 0.25% trypsin in 9 mmol/L CaCl 2 /50 mmol/L Tris-HCl, pH 7.8, for 30 minutes at room temperature for antigen retrieval. After blockade with goat serum (3%), samples were incubated overnight (4 °C) with the following primary antibodies diluted in 0.1% PBS/BSA: mouse anti-human VEGF-A 165 b (5 μg/ml, cat# MAB3045, R&D Systems), or control IgG (5 μg/ml, cat# MAB002, R&D Systems). Specific labeling was detected with a biotin-conjugated goat anti-mouse secondary antibody (1:500 dilution, Dako) or with Alexa Fluor 594 goat anti-mouse secondary antibody (1:1000 dilution, cat# A11005, ThermoFisher Scientific). For double immunofluorescence analysis, VEGF-A 165 b was detected with a mouse anti-human VEGF-A 165 b antibody (5 μg/ml, cat# MAB3045, R&D Systems), CD31 with a rabbit polyclonal anti-human-CD31 (1:50 dilution, cat# ab32457, Abcam) and VEGFR2 with a rabbit polyclonal anti human-VEGFR2 (1:20 dilution, cat# ab39638, Abcam). Specific labeling was detected with an Alexa Fluor 594 goat anti-mouse secondary antibody (1:1000 dilution, cat# A11005, ThermoFisher Scientific) or an Alexa Fluor 488 goat anti-rabbit secondary antibody (1:1000 dilution, cat# A11034, ThermoFisher Scientific). Fields from each infarct or control sections were captured, digitized and then analyzed with Image-Pro Plus analysis software (Media Cybernetics, Inc., Rockville, MD). Scoring was performed blinded on coded slides.
Statistical analysis.
We assessed normality of distribution with the Kolmogorov-Smirnov test. Continuous normally distributed data were expressed as the mean ± the standard deviation of the mean, whereas non-parametric data were expressed as the median and the interquartile range. For comparisons of two groups, Student's t test was used for data that passed both normality (Kolmogorov-Smirnov test) and equality of variance (Levene's test); otherwise, the non-parametric Mann Whitney U test was used. For comparisons among multiple groups, one-way analysis of variance (ANOVA) followed by post hoc analysis (Bonferroni test) was used in data that passed both normality and equality of variance; otherwise, the non-parametric Kruskal-Wallis test followed by Dunn's post hoc analysis was used. The Spearman correlation test was used to analyze the correlation between VEGF-A 165 b levels and different clinical variables of the patients. Group percentages were compared using the Chi-square test or Fisher's exact test where appropriate. Data were analyzed using GraphPad software (GraphPad Prism 4, Inc, La Jolla, CA). Data were considered statistically significant at p<0.05.
